To challenge this concept, we analysed the impact of the genetic alterations (on KRAS, PIK3CA, PTEN) and of the organ of origin in determining the role of each class I PI3K in tumour cell migration and cytotoxic sensitivity in response to PI3K inhibitors. This evidence concerns the gene PIK3CB and neoplasm.